Research programme: protein drug conjugates - Avacta/Glythera

Drug Profile

Research programme: protein drug conjugates - Avacta/Glythera

Alternative Names: AVA 006

Latest Information Update: 09 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Avacta; Glythera
  • Developer Glythera
  • Class Antineoplastics; Drug conjugates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 03 Aug 2016 Avacta has patent protection for Affimer technology in Europe, Japan and USA
  • 03 Aug 2016 Avacta receives Notice of Allowance for Affimer technology in USA
  • 14 Jul 2016 Avacta and Glythera agree to co-develop Protein-drug conjugates for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top